Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-hematopoietic stem cell population (null)
- Target
- null
- Molecular classification
- Other (stem/progenitor cell population, not a canonical molecular family: includes stromal/mesenchymal, endothelial, embryonic-like, etc.)
01
Overview
Non-hematopoietic stem cell populations are primitive, self-renewing cells found in adult bone marrow, umbilical cord blood, and other tissues, able to differentiate into non-blood cell types such as bone, cartilage, fat, endothelial, neuronal, and epithelial cells[1][3][2]. They include cell types such as mesenchymal stromal cells, endothelial progenitor cells, and very small embryonic-like stem cells, and are the subject of intense research for their roles in tissue repair, regeneration, and cell-based therapy[3]. These populations do not function as defined molecular therapeutic targets (like a receptor or enzyme) but are rather broad cell groups with regenerative potential, identifiable by characteristic cell surface markers and differentiation capacity[1][3].
- Other names
- Mesenchymal stromal cells (MSC)Endothelial progenitor cells (EPC)Very small embryonic-like stem cells (VSEL)Unrestricted somatic stem cells (USSC)Multi-lineage progenitor cells (MLPC)Neuronal progenitor cells
02
Mechanism of action
null
03
Biological functions
Cell differentiationTissue regenerationRepair of injured tissueSelf-renewalHomeostasis and support of non-blood cell types (e.g., bone, cartilage, epithelial)Enhancing neovascularization
04
Disease associations
Cancer (possible involvement via repair and regeneration, but not a defined cancer target)Cardiovascular disease (used in research for tissue regeneration and neovascularization)Tissue injury and repair (regenerative medicine)Other (cell-based therapies, tissue engineering)
05
Safety considerations
Potential for tumorigenesis (especially with pluripotent cells)Immunogenicity/rejection (in allogeneic settings)Incomplete engraftment/differentiationOff-target differentiation and lack of lineage specificity
06
Biomarkers
CD13, CD29, CD44, CD90, CD105 (positive for MSCs)CD14, CD34, CD45 (negative for non-hematopoietic fraction of MSCs)Oct-4, Nanog, SSEA-4, CD31, KDR, vWF, CD146 (differ by subtype for other progenitors, e.g., VSEL, EPC)
Beyond the preview
Go deeper on Non-hematopoietic stem cell population (null).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Non-hematopoietic stem cell population (null).